Search

Displaying results 8681 - 8690 of 10000 in total
  1. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    It is composed of two heavy chain molecule fragments and 2 light chain fragments. … Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity

  2. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    Schizophrenia is a complex mental illness and impacts approximately 1% of the population. … [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  3. Drug

    Mianserin

    go.drugbank.com/drugs/DB06148
    ApprovedWithdrawn

    A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingSynonyms: 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine
  4. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin, also known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

    Categories: 2-Amino-1-Phenylethanol Derivatives, Cytochrome P-450 Substrates
  5. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

    Categories: 4-Quinolones, Heterocyclic Compounds, 2-Ring
  6. Drug

    Talotrexin

    go.drugbank.com/drugs/DB06178
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

    Categories: Adrenergic beta-3 Receptor Agonists
  8. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  9. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. … Based on existing clinical data, Tolperisone is not sedating and does not interact with alcohol.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  10. Drug

    Levocetirizine

    go.drugbank.com/drugs/DB06282
    ApprovedInvestigational

    Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. … [L7694] Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

    Mixtures: ANTISS® D, ANTISS® DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates